Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial.

Landi L, Chiari R, Tiseo M, D'Incà F, Dazzi C, Chella A, Delmonte A, Bonanno L, Giannarelli D, Cortinovis DL, De Marinis F, Borra G, Morabito A, Gridelli C, Galetta D, Barbieri F, Grossi F, Capelletto E, Minuti G, Mazzoni F, Verusio C, Bria E, Alì G, Bruno R, Proietti A, Fontanini G, Crinò L, Cappuzzo F.

Clin Cancer Res. 2019 Aug 15. pii: clincanres.0994.2019. doi: 10.1158/1078-0432.CCR-19-0994. [Epub ahead of print]

PMID:
31416808
2.

Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer.

D'Arcangelo M, D'Incecco A, Ligorio C, Damiani S, Puccetti M, Bravaccini S, Terracciano L, Bennati C, Minuti G, Vecchiarelli S, Landi L, Milesi M, Meroni A, Ravaioli S, Tumedei MM, Incarbone M, Cappuzzo F.

Oncotarget. 2019 Jan 15;10(5):561-572. doi: 10.18632/oncotarget.26529. eCollection 2019 Jan 15.

3.

Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC).

Vecchiarelli S, Passiglia F, D'Incecco A, Gallo M, De Luca A, Rossi E, D'Incà F, Minuti G, Landi L, Bennati C, Spreafico M, D'Arcangelo M, Mazza V, Normanno N, Cappuzzo F.

Oncotarget. 2018 Apr 3;9(25):17554-17563. doi: 10.18632/oncotarget.24785. eCollection 2018 Apr 3.

4.

Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.

Lambertini M, Ferreira AR, Di Meglio A, Poggio F, Puglisi F, Sottotetti F, Montemurro F, Poletto E, Bernardo A, Risi E, Dellepiane C, Sini V, Minuti G, Grasso D, Fancelli S, Del Mastro L.

Clin Breast Cancer. 2017 Dec;17(8):601-610.e2. doi: 10.1016/j.clbc.2017.04.002. Epub 2017 Apr 11.

PMID:
28479052
5.

microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.

Gasparini P, Cascione L, Landi L, Carasi S, Lovat F, Tibaldi C, Alì G, D'Incecco A, Minuti G, Chella A, Fontanini G, Fassan M, Cappuzzo F, Croce CM.

Proc Natl Acad Sci U S A. 2015 Dec 1;112(48):14924-9. doi: 10.1073/pnas.1520329112. Epub 2015 Nov 16.

6.

Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly.

Minuti G, D'Incecco A, Cappuzzo F.

Drugs Aging. 2015 Nov;32(11):907-16. doi: 10.1007/s40266-015-0305-6. Review.

PMID:
26446154
7.

MET deregulation in breast cancer.

Minuti G, Landi L.

Ann Transl Med. 2015 Aug;3(13):181. doi: 10.3978/j.issn.2305-5839.2015.06.22. Review.

8.

Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.

Lambertini M, Ferreira AR, Poggio F, Puglisi F, Bernardo A, Montemurro F, Poletto E, Pozzi E, Rossi V, Risi E, Lai A, Zanardi E, Sini V, Ziliani S, Minuti G, Mura S, Grasso D, Fontana A, Del Mastro L.

Oncologist. 2015 Aug;20(8):880-9. doi: 10.1634/theoncologist.2015-0020. Epub 2015 Jun 22.

9.

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.

D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J, Coppi E, Chella A, Fontanini G, Filice ME, Tornillo L, Incensati RM, Sani S, Crinò L, Terracciano L, Cappuzzo F.

Br J Cancer. 2015 Jan 6;112(1):95-102. doi: 10.1038/bjc.2014.555. Epub 2014 Oct 28.

10.

Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.

Landi L, Tiseo M, Chiari R, Ricciardi S, Rossi E, Galetta D, Novello S, Milella M, D'Incecco A, Minuti G, Tibaldi C, Salvini J, Facchinetti F, Haspinger ER, Cortinovis D, Santo A, Banna G, Catino A, GiajLevra M, Crinò L, de Marinis F, Cappuzzo F.

Clin Lung Cancer. 2014 Nov;15(6):411-417.e4. doi: 10.1016/j.cllc.2014.07.002. Epub 2014 Aug 16.

11.

Protein kinase inhibitors to treat non-small-cell lung cancer.

Minuti G, D'Incecco A, Landi L, Cappuzzo F.

Expert Opin Pharmacother. 2014 Jun;15(9):1203-13. doi: 10.1517/14656566.2014.909412. Epub 2014 Apr 19. Review.

PMID:
24745764
12.

Targeted therapy for NSCLC with driver mutations.

Minuti G, D'Incecco A, Cappuzzo F.

Expert Opin Biol Ther. 2013 Oct;13(10):1401-12. doi: 10.1517/14712598.2013.827657. Epub 2013 Aug 10. Review.

PMID:
23930754
13.

MET overexpression and gene amplification in NSCLC: a clinical perspective.

Landi L, Minuti G, D'Incecco A, Salvini J, Cappuzzo F.

Lung Cancer (Auckl). 2013 Jun 18;4:15-25. doi: 10.2147/LCTT.S35168. eCollection 2013. Review.

14.

Targeting c-MET in the battle against advanced nonsmall-cell lung cancer.

Landi L, Minuti G, D'Incecco A, Cappuzzo F.

Curr Opin Oncol. 2013 Mar;25(2):130-6. doi: 10.1097/CCO.0b013e32835daf37. Review.

PMID:
23385860
15.

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer.

Minuti G, Cappuzzo F, Duchnowska R, Jassem J, Fabi A, O'Brien T, Mendoza AD, Landi L, Biernat W, Czartoryska-Arłukowicz B, Jankowski T, Zuziak D, Zok J, Szostakiewicz B, Foszczyńska-Kłoda M, Tempińska-Szałach A, Rossi E, Varella-Garcia M.

Br J Cancer. 2012 Aug 21;107(5):793-9. doi: 10.1038/bjc.2012.335. Epub 2012 Jul 31.

16.

Consequences of targeted treatments for second-line therapy.

De Maio E, Tibaldi C, D'Incecco A, Bursi S, Barbara C, Cupini S, Di Marsico R, D'Arcangelo M, Landi L, Minuti G, Cappuzzo F.

Ann Oncol. 2010 Oct;21 Suppl 7:vii234-40. doi: 10.1093/annonc/mdq280. Review.

PMID:
20943621
17.

Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer.

Fontana A, Bocci G, Galli L, D'Arcangelo M, Derosa L, Fioravanti A, Orlandi P, Barletta MT, Landi L, Bursi S, Minuti G, Bona E, Grazzini I, Danesi R, Falcone A.

J Am Geriatr Soc. 2010 May;58(5):986-8. doi: 10.1111/j.1532-5415.2010.02833.x. No abstract available.

PMID:
20722827

Supplemental Content

Loading ...
Support Center